On August 1, Japan's Kyowa Kirin Pharmaceuticals made an announcement about its “reorganization” of its China business. According to the report of “E Drug Manager”, this multinational pharmaceutical company, which is ranked among the top 50 in the world, sold its China market related interests to Hong Kong Weikeng Pharmaceutical Group at a modest transfer price of 720 million RMB.
This means that Concordia Kirin will not continue to operate directly in China, but rather packaged to an “agent” to operate the Chinese market. Why is Concordia Kirin discontinuing its direct operations in China?
First, Concordia Kirin does not operate on a large scale in China
The annual report shows that China's revenue only accounts for 3% of its global sales revenue. According to the author's understanding, in recent years, the revenue of Concordia Kirin's China region has always hovered in the small hundreds of millions of RMB. In recent years, although Concordia Kirin Pharmaceuticals has new products approved in China and included in the medical insurance, but in the operating system is exceptionally conservative, even if there is a new drug product newly included in the medical insurance, the Chinese region can not get the marketing budget from the headquarters - such a practice is really surprising.
Secondly, the innovative drug market in China is small
It's a bit counter-intuitive that China, with 1.4 billion people and rapidly aging, has a total pharmaceutical market capacity of about RMB 3.36 trillion, making it the world's second-largest single-country pharmaceutical market. However, according to research by the brokerage firm in question, the overall capacity of innovative drugs in China is only about RMB 150-200 billion, which is only about 3% of the global innovative drug market capacity. The total volume of innovative drugs in China is less than 1/15 of that of the United States, and less than half of that of Japan's innovative drug market.
Is it that China has no spending power? Many familiar luxury brands can even account for 20-40% of global sales in China. In contrast, China's sales of innovative drugs are “so small that it is hard to understand”, and does not match the perception that “China is a big market” that we advocate when negotiating drug prices with multinational drug companies.
Third, the pricing of innovative drugs in China is low
To be included in the medical insurance, China's innovative drugs must be negotiated with the competent parties, and the result of the negotiations is often the lowest price in the world. Over the past few years, studies have shown that China's innovative drug prices are at the bottom of the global innovative drug prices - about 20% of the lowest prices in the world. Zebutinib, the original innovative drug developed by China's innovative drug company Baizi Shenzhou, is sold in the United States at more than 10 times the price in China, and furaquintinib, independently developed by Hehuang Pharmaceuticals, is sold in the United States at 24 times the price in China. Such a huge price difference will undoubtedly pose great pressure on multinational drug companies to balance the global drug price system.
Fourth, corruption is hard to cure and our pharmaceutical market is complex
Carry out global marketing of large pharmaceutical companies are mainly listed companies, they are subject to strict regulation in Europe and the United States - especially the United States of America for pharmaceutical companies corruption regulation is very strict, and the United States of America on the country's multinational enterprises listed on the implementation of the long arm of the jurisdiction of the corruption in other countries will also be subject to heavy penalties.
China's medical market is very special, these years, “anti-corruption” continues to deepen, and has made a lot of achievements, can be said to be the fruit of war. But in general, the current medical service fee is still very low, medical related personnel through drugs, equipment rent-seeking, seeking income “compensation” there is still a systemic basis for anti-corruption in this case, such as raising the soup to stop the boil, the problem is always endless.
Such an environment may be too complicated and difficult to adapt to for a Japanese company like Concordia Kirin, which is not flexible enough to operate.
If we put ourselves in the perspective of a business operator looking at the Chinese innovative drug market, what conclusions would we draw?
What to do in a market with limited capacity, a disruptive effect on global new drug pricing, a complex operating environment, and significant compliance challenges?
Concordia Kirin's choice is not surprising, and I believe that its management has thought deeply and made a careful decision before deciding to “exit”.
We must be alert to the fact that for multinational drug companies, China's innovative drug market is becoming a “meatless market to eat, a shame to abandon, and a hot market to hold”. If the pricing policy of innovative drugs is not adjusted and the market operating environment is not effectively improved, multinational pharmaceutical companies will regard China as a medium-sized market, aiming at safe profitability, and no longer regard China as a strategic emerging market. Once this judgment is made, it is in line with business logic to withdraw from direct sales and choose the agency system. However, this choice is not in line with China's policy orientation of deepening reform and promoting high-level opening up, and is not conducive to the progress of China's pharmaceutical industry.
The good thing is that recently China's management has been concerned about the plight of innovative drugs, from the approval, access, health insurance policy in many aspects of a number of new initiatives, so that innovative drug track entrepreneurs, operators feel the slightest warmth. To paraphrase AZ (AstraZeneca) Global Executive President Wang Lei, “the times belong to the optimists”, but to make entrepreneurs and start-ups optimistic, I'm afraid that the authorities need to launch a more thorough and more vigorous reform.